Genetic landscape and survival of patients treated with HMA+VEN combinations. (A) The genetic landscape of 266 patients treated with HMA+VEN combinations, displaying the frequency of mutations (mut) present in ≥10 patients. Notably, most muts (other than those used for current risk-group assignment) could be found across all ELN24 risk groups. (B) Within the ELN24 favorable-risk subgroup, patients with mutated NPM1, IDH1, IDH2, or DDX41 experienced particularly favorable survival compared with other included patients. (C-D) Within the ELN24 intermediate-risk subgroup, KRAS muts but not NRAS muts were associated with inferior survival. (E) When evaluating other RAS/receptor tyrosine kinase signaling pathway gene mut’s impact on survival, PTPN11 muts correlated with inferior outcomes. CI, confidence interval; Fav/Int, favorable/intermediate risk; HR, hazard ratio.